## Claims:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

$$(R^2)_m$$
 $(CH_2)_p$ 
 $Q$ 
 $O = S = O$ 
 $A$ 
 $(I)$ 

5

wherein

 $R^1$  and  $R^2$  independently represent hydrogen or  $C_{1-6}$  alkyl or  $R^1$  is linked to  $R^2$  to form a group  $(CH_2)_2$ ,  $(CH_2)_3$  or  $(CH_2)_4$ ;

10 p represents 1 or 2;

m represents an integer from 1 to 4, when m is an integer greater than 1, two  $R^2$  groups may instead be linked to form a group  $CH_2$ ,  $(CH_2)_2$  or  $(CH_2)_3$ ;

Opposents a group of formula (i), (ii), (iii) or (iv):

$$(R^3)_n \xrightarrow{X} Y \qquad \qquad R^{3\epsilon}$$

$$[S]$$

$$(i)$$

15

$$(\mathbb{R}^{3})_{n} \xrightarrow{X} \mathbb{R}^{3a}$$

$$(ii)$$

$$(R^3)_n \xrightarrow{N} (R^4)_s$$
(iii)

20

$$(R^3)_r \xrightarrow{[S]} (R^4)_q$$

wherein [N] and [S] represent the attachment points for the groups

$$(R^2)_m$$
 $(CH_2)_p$ 
 $O=S=O$ 
and  $A$  respectively;

5

one of X and Y represents -N= and the other represents  $-N(R^5)$ -;

 $R^3$  and  $R^4$  independently represent hydrogen, halogen, cyano, -CF<sub>3</sub>, -OCF<sub>3</sub>, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl or a group –CONR<sup>6</sup>R<sup>7</sup>;

R<sup>3a</sup> and R<sup>5</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl;

10 R<sup>6</sup> and R<sup>7</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fix the form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n and q independently represent 1 or 2;

r and s independently represent an integer from 1 to 3;

15 A represents a group -Ar<sup>1</sup> or - Ar<sup>2</sup>Ar<sup>3</sup>;

 $Ar^1$ ,  $Ar^2$  and  $Ar^3$  independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy,  $C_{1-6}$  alkyl,

trifluoromethanesulfonyloxy, pentafluoroethyl,  $C_{1-6}$  alkoxy, aryl $C_{1-6}$  alkoxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl $C_{1-6}$  alkoxy,  $C_{1-6}$  alkanoyl,  $C_{1-6}$  alkoxycarbonyl,  $C_{1-6}$  alkylsulfonyl,  $C_{1-6}$  alkylsulfonyloxy,  $C_{1-6}$  alkylsulfonyl $C_{1-6}$  alkylsulfonyloxy, arylsulfonyl $C_{1-6}$  alkylsulfonamido,  $C_{1-6}$  alkylsulfonamido, alkylsulfonamido,  $C_{1-6}$  alkyl, arylsulfonamido, alkylsulfonamido,

arylcarboxamido, arylsulfonamidoC<sub>1-6</sub> alkyl, arylcarboxamidoC<sub>1-6</sub> alkyl, aroyl, aroylC<sub>1-6</sub> alkyl, arylC<sub>1-6</sub> alkyl, arylC<sub>1-6</sub> alkanoyl, or a group CONR<sup>8</sup>R<sup>9</sup> or SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, wherein R<sup>8</sup> and R<sup>9</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom:

30 or solvates thereof.

WO 03/080608 PCT/EP03/03195

2. A compound according to claim 1 which is a compound of formula E1-E16 or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or claim 2 for use in therapy.

5

- 4. A compound according to claim 1 or claim 2 for use in the treatment of depression, anxiety, obesity and cognitive memory disorders.
- 5. A pharmaceutical composition which comprises a compound according to claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.